Disciformycins A and B: 12-membered macrolide glycoside antibiotics from the myxobacterium Pyxidicoccus fallax active against multiresistant staphylococci

Frank Surup; Konrad Viehrig; Kathrin I Mohr; Jennifer Herrmann; Rolf Jansen; Rolf Müller

doi:10.1002/anie.201406973

Disciformycins A and B: 12-membered macrolide glycoside antibiotics from the myxobacterium Pyxidicoccus fallax active against multiresistant staphylococci

Angew Chem Int Ed Engl. 2014 Dec 1;53(49):13588-91. doi: 10.1002/anie.201406973. Epub 2014 Oct 7.

Authors

Frank Surup¹, Konrad Viehrig, Kathrin I Mohr, Jennifer Herrmann, Rolf Jansen, Rolf Müller

Affiliation

¹ Helmholtz Center for Infection Research (HZI), Department Microbial Drugs, Inhoffenstrasse 7, 38124 Braunschweig (Germany); German Center for Infection Research (DZIF), Location: Braunschweig (Germany).

PMID: 25294799
DOI: 10.1002/anie.201406973

Abstract

Two macrolide glycosides with a unique scaffold were isolated from cultures of the myxobacterium Pyxidicoccus fallax. Their structures, including absolute configurations, were elucidated by a combination of NMR, MS, degradation, and molecular modeling techniques. Analysis of the proposed biosynthetic gene cluster led to insights into the biosynthesis of the polyketide and confirmed the structure assignment. The more active compound, disciformycin B, potently inhibits methicillin- and vancomycin-resistant Staphylococcus aureus.

Keywords: antibiotics; biosynthesis; myxobacteria; polyketides; secondary metabolites.

MeSH terms

Anti-Bacterial Agents / chemistry*
Anti-Bacterial Agents / isolation & purification
Anti-Bacterial Agents / pharmacology*
Humans
Macrolides / chemistry*
Macrolides / isolation & purification
Macrolides / pharmacology*
Methicillin-Resistant Staphylococcus aureus / drug effects
Myxococcales / chemistry*
Staphylococcal Infections / drug therapy*
Staphylococcus aureus / drug effects*
Vancomycin Resistance

Substances

Anti-Bacterial Agents
Macrolides